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        Introduction 
  MicroRNAs (miRNAs) are 21  –  22 nucleotide molecules that 
regulate the stability or translational effi  ciency of targeted 
mRNAs. Derived from nuclear precursor RNAs, initial process-
ing occurs by the internuclease Drosha to release pre-miRNAs 
of 60  –  70 nucleotides in length from pri-miRNA. Subsequent 
transport to the cytoplasm by exportin-5 results in processing 
by the internuclease Dicer to generate the    22-nucleotide  ma-
ture miRNA (  Yi et al., 2003  ;   Lund et al., 2004  ;   Zhang et al., 
2004  ). The base pairing interactions between miRNAs and their 
target mRNAs, often within the 3     untranslated region (UTR) 
of target genes, results in the degradation of target mRNAs 
(  Ambros, 2004  ;   Cullen, 2004  ) or inhibition of their translation 
( Lai, 2002 ). To date, 533 miRNAs have been identifi  ed in humans 
(miRBase Sequence Database version 10.0, released in August 
2007; http://microrna.sanger.ac.uk/sequences/). It has been pro-
posed that, as each vertebrate miRNA may bind to as many as 
200 gene targets, miRNAs potentially control the expression of 
about one-third of human mRNAs (  Krek et al., 2005  ). 
  Several independent lines of evidence support a role for 
miRNAs in human cancer (  Calin et al., 2005  ;   Croce and Calin, 
2005 ,   2006 ;   He  et  al.,  2005 ,   2007 ).  miRNA-encoding  genes  are 
frequently located at fragile sites, as well as in minimal regions 
of loss of heterozygosity, minimal regions of amplifi  cation, 
and in common breakpoint regions involved in cancers (  Calin 
et al., 2004  ). Aberrant expression of miRNAs or mutations of 
miRNA genes have been described in many types of tumors. 
Let-7 abundance is reduced in several cancers, including lung 
cancer (  Takamizawa et al., 2004  ), and let-7 was reported to 
regulate tumor growth by targeting the   ras   gene (  Johnson et al., 
2005  ). miR-15a and miR16-1 were deleted and/or down-
regulated in     70% of patients with chronic lymphocytic leu-
kemia (  Calin et al., 2002  ). miR-15a/16-1 induced apoptosis by 
inhibiting BCL-2 (  Cimmino et al., 2005  ). The miR-34 family is 
an important component of the p53 tumor suppressor network 
(  He et al., 2007  ). The human miR-17/20 cluster  ’  s genomic 
  location, chromosome 13q31, correlates with loss of hetero-
zygosity in several different cancers, including breast cancer 
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MCF-7, and T-47D), one nontumorigenic breast epithelial cell 
line (MCF-10A), and two nonbreast tumor cell lines (HeLa and 
293T; Fig. S1, available at http://www.jcb.org/cgi/content/full/
jcb.200801079/DC1). The expression of miR-17-5p and miR-20a 
was low to undetectable in at least six of the nine breast cancer 
cell lines compared with either nontumorigenic breast epithelial 
cell (MCF-10A) or nonbreast cancer cell lines (HeLa and 293T). 
The reduced expression of miR-17/20 in breast cancer cells 
suggested the miRNA cluster may have a unique function dur-
ing breast tumorigenesis. 
  To further investigate the role of miR-17/20 in breast can-
cer, a retroviral vector encoding the miR-17/20 cluster was used 
to infect MCF-7 and the NAFA cell line, which is derived from 
MMTV-ErbB2 transgenic mice breast tumors (  Fig. 1 A  ). North-
ern blotting confi  rmed the increased expression of the compo-
nents in the miR-17/20 cluster (miR-17-5p, 18a, 19a, 19b, 20a, 
and 92) in the transduced cells (  Fig. 1 B  ). Cellular proliferation 
assays were performed on the miR-17/20  –  transduced cells. 
miR-17/20 expression inhibited MCF-7 cell proliferation and 
cell growth by     60% after 72 h (  Fig. 1, C and D  ). To determine 
if miR-17/20 regulated estrogen-dependent cellular prolifera-
tion, MCF-7 cells were treated with estrogen (17   -estradiol). 
Both estrogen-dependent and -independent cell proliferation 
was inhibited by miR-17/20 (  Fig. 1 E  ). Furthermore, miR-17/20 
(  Eiriksdottir et al., 1998  ;   Lin et al., 1999  ). The expression and 
function of miRNA varies by cell type. The miR-17/20 clus-
ter functions as a tumor suppressor in the human B cell line 
P493-6 by decreasing   E2F1   expression, thereby inhibiting   myc -
induced cell proliferation (  O  ’  Donnell et al., 2005  ). In contrast, 
in both lung cancer and lymphomas, expression of this miRNA 
cluster was increased, enhancing cell growth (  Hayashita et al., 
2005  ;   He et al., 2005  ). As the same miRNA performs dif-
ferent functions through distinct pathways dependent on the 
tissue or cell type, it is important to understand the mecha-
nisms by which miRNA regulates the cell cycle and thereby 
tumorigenesis. 
  The onset and progression of tumorigenesis involves eva-
sion of apoptotic signals, sustained cellular proliferation, and 
the ability to promote tumor neoangiogenesis.   Cyclin D1   over-
expression is found in     50% of human breast cancers (  Fu et al., 
2004  ). Antisense to   cyclin D1   abrogated the growth of ErbB2-
induced breast tumors, and   cyclin D1 
   /       mice are resistant to the 
induction of tumors either in the mammary gland or the skin in-
duced by oncogenic  ras  or  ErbB2  ( Lee et al., 2000 ;  Fu et al., 2004 ). 
A subset of miRNAs are regulated by oncogenic   myc   and   ras  
(  Johnson et al., 2005  ;   O  ’  Donnell et al., 2005  ), but the require-
ment for cell cycle proteins in the regulation of miRNA is still 
unknown. Furthermore, the understanding of the mechanism by 
which specifi  c oncogenes regulate miRNA expression and func-
tion is limited. 
  By a large-scale miRnome analysis using miRNA chips on 
mouse mammary tumor virus (MMTV)  –    cyclin D1   transgenic 
mice and   cyclin D1   knockout mice, we determined a subset of 
miRNAs controlled by   cyclin D1 . These studies identifi  ed a novel 
regulatory mechanism in which   cyclin D1   induces a miRNA 
signature that includes miR-17-5p and miR-20a through the 
binding of the miR-17/20 promoter region. miR-17/20 in turn 
attenuates   cyclin D1   abundance via a negative feedback loop to 
regulate   cyclin D1   through a conserved 3     UTR miRNA binding 
site. Given the central role for   cyclin D1   in cellular differentia-
tion and tumorigenesis, the studies herein, which demonstrate 
that miRNAs determine   cyclin D1   abundance, have broad im-
plications for cancer biology. This work demonstrates additional 
regulatory mechanisms between oncogenes and tumor suppres-
sor miRNAs that act in concert with other factors to limit onco-
gene function. 
  Results 
  miR-17/20 down-regulates   cyclin D1   
expression and suppresses breast cancer 
cell proliferation 
  The miR-17/20 cluster located on chromosome 13q31 encodes 
six miRNAs within an    1-kb  region. Amplifi  cation and overex-
pression of miR-17/20 has been described in B cell lymphomas 
(  He et al., 2005  ) and lung cancers (  Hayashita et al., 2005  ). 
miR-17-5p and miR-20a are key important components of the 
miR-17/20 cluster. To characterize the miR-17/20 expression 
in breast cancer cell lines, Northern blot analysis was performed 
of nine breast cancer cell lines (MDA-MB-231, BT-474, MDA-
MB-453, Hs578T, MDA-MB-486, SKBR-3, MDA-MB-361, 
  Figure 1.       miR-17/20 inhibits breast cancer cell proliferation.   (A) The geno-
mic region of miR-17/20 cluster on chromosome 13q31 and the vector 
structure for miRNA17/20 overexpression. (B) Northern blot analysis 
demonstrating the increased expression of the six members of miR-17/20 
cluster in the miR-17/20  –  transduced MCF-7 cells. tRNA served as loading 
control. (C and D) Cellular proliferation assay; (E) an MTT assay; and 
(F) a colony formation assay consistently showed the inhibition of MCF-7 
cell proliferation by miR-17/20 overexpression. Cellular proliferation as-
says and the MTT assay were performed in three independent experiments 
(data are equal to mean   ±   SEM). *, P   <   0.01.     511 CYCLIN     D1/  MICRO  RNA 17/20 REGULATORY LOOP   • Yu et al. 
by miR-17/20 (  Fig. 3 A  ). Both anti-mirs reversed the antiprolifera-
tive function of miR-17/20 (  Fig. 3 B  ), which is consistent with 
the functional role of cyclin D1. The abundance of   AIB1 ,  a  target 
of miR-17-5p repression, was inhibited as previously described 
by miR-17/20 (  Hossain et al., 2006  ). The down-regulation of 
  cyclin D1   and   AIB1   by miR-17/20 could be rescued by either 
anti – miR-17-5p  or  anti – miR-20a  ( Fig.  3 A ). 
  To determine whether endogenous miR-17/20 regulates 
  cyclin D1   abundance and cell proliferation, MCF-7 cells were 
transfected with anti  –  miR-17-5p and anti  –  miR-20a. Inhibition of 
these endogenous miRNAs  ’   function enhanced cellular pro-
liferation and cyclin D1 abundance (Fig. S3, available at http://
www.jcb.org/cgi/content/full/jcb.200801079/DC1). 
inhibited MCF-7 contact-independent growth determined through 
colony formation assays (  Fig. 1 F  ). 
  miR-17/20 arrests the cell cycle at the G  1   
phase in a   cyclin D1    –  dependent manner 
  To determine the mechanism by which miR-17/20 suppressed 
breast cancer cell proliferation, the abundance of key cell cycle 
regulatory proteins was assessed. Cyclin D1 abundance is rate 
limiting for MCF-7 cell DNA synthesis.   Cyclin D1   expression 
was inhibited     50% by miR-17/20 overexpression, whereas 
cyclin E, Cdk 4, and Cdk 6 expressions were unaltered in miR-
17/20 – transduced  cells  ( Fig.  2 A ). 
  To examine the functional interrelationship between 
miR-17/20 and cyclin D1,   cyclin D1   siRNA was used to trans-
fect miR-17/20  –  transduced MCF-7 cells (  Fig. 2 B  ). miR-17/20  –
  transduced MCF-7 cells were starved with 5% charcoal-stripped 
serum for 48 h, and cellular DNA synthesis was stimulated by 
the addition of 10% normal FBS. Cell cycle analysis was con-
ducted before serum stimulation and upon 16 h of serum treat-
ment. The proportion of cells corresponding to the proportion of 
cells in the S and G  2  /M phase was lower in miR-17/20  –  transduced 
MCF-7 cells (25.9   ±   0.6% vs. 9.9   ±   0.3%) than that in control 
cells (31.1   ±   0.4% vs. 14.9   ±   0.8%;   Fig. 2 C  ). The G  0 /G 1   phase  was 
increased in miR-17/20  –  transduced MCF-7 cells (62.4   ±   0.6%) 
compared with control cells (51.8   ±   0.1%). The inhibition of 
S phase by miR-17/20 was dependent on cyclin D1, as cyclin 
D1 knockdown with siRNA abrogated the G  1   phase and S phase 
differences between miR-17/20 overexpressed MCF-7 cells 
(G  0 /G 1  : 67.5%   ±   0.7%; S, 14.8   ±   1.0%) and control cells (G  0 /G 1 : 
68.8%   ±   0.5%; S, 14.4   ±   0.6%;   Fig. 2 C  ). 
  MCF-7 cells express abundant cyclin D1. In contrast with 
MCF-7 cells, transduction of MCF-10A and BT-474 cells, which 
have low abundance of cyclin D1 (  Fig. 3  ), with the miR-17/20 
cluster had no demonstratable effect on DNA synthesis induced 
by FBS (Fig. S2, available at http://www.jcb.org/cgi/content/full/
jcb.200801079/DC1). These results indicate that the inhibition 
of G  1  /S transition by miR-17/20 is cyclin D1 dependent. 
  The ErbB2 oncogene is overexpressed or amplifi  ed in 
    30% of human breast cancers and is suffi  cient for mammary 
tumor generation when targeted to the mammary gland in trans-
genic mice. The NAFA cell line is derived from MMTV-ErbB2 
transgenic tumors. To determine the role of miR-17/20 cluster 
in ErbB2-mediated tumor growth, the NAFA cell line was trans-
duced with the expression vector encoding an miR-17/20 clus-
ter (  Fig. 1 A  ). The expression of miR-17-5p and miR-20a was 
induced in NAFA cells transduced with the miRNA17/20 clus-
ter (  Fig. 2 D  ). miR-17/20 expression inhibited proliferation of 
NAFA cells (  Fig. 2 E  ). 
  To examine further the specifi  city with which miR-17/20 
inhibits   cyclin D1   abundance, chemically modifi  ed miRNA 
inhibitors (anti-mir) were used to block miRNA function. 
The miR-17/20 locus  –  transduced MCF-7 cells were transfected 
with anti – miR-17-5p  and  anti – miR-20a,  which  can  specifi  cally in-
teract with miR-17-5p and miR-20a, respectively, to block their 
function. Cyclin D1 abundance is rate-limiting in MCF-7 cells 
for DNA synthesis and cell proliferation. Both anti  –  miR-17-5p 
and anti  –  miR-20a rescued the inhibition of   cyclin D1   abundance 
  Figure 2.       miR-17/20 arrests cell cycle at the G  1   phase in a cyclin D1  – 
dependent manner.   (A) Western blot analysis of the   cyclin D1  ,   CDK4  , 
  CDK6  , and   cyclin E   expression in miR-17/20  –  transduced cells.   GDI   
served as loading control. (B) MCF-7 cells were transfected with cyclin 
D1 siRNA and control siRNA. Western blotting demonstrated the efﬁ  cient 
knockdown of cyclin D1 after 72 h of siRNA treatment. (C) Cell cycle 
analysis indicated the increased population of cells at G  0  /G  1   phase and 
decreased S and G  2  /M phase cells in miR-17/20  –  transduced MCF-7 cells 
under a cyclin D1 background. This difference was abolished by knockdown 
of cyclin D1 in cells. The analysis was performed in triplicates (data 
are equal to mean   ±   SEM). (D) Northern blot demonstrated the increased 
expression of miR-17/20 in the miR-17/20  –  transduced NAFA cells. 
tRNA served as a loading control. (E) The MTT assay showed the inhibited 
cell proliferation of NAFA cells by miR-17/20 transduction. The assay 
was performed in three independent experiments, and the data are pre-
sented as the mean   ±   SEM.     JCB • VOLUME 182 • NUMBER 3 • 2008  512 
conducted. No signifi  cant difference in cyclin D1 mRNA levels 
was observed between miR-17/20  –  transduced cells and control 
cells (  Fig. 4 A  ). This result suggests that the miR-17/20 cluster 
regulates   cyclin D1   gene expression at the posttranscriptional 
level. Alignment of the human and mouse   cyclin D1   mRNA  3   
UTRs identifi  ed a conserved miR-17/20  –  binding site (  Fig. 4 B  ). 
The miR-17/20  –  binding site (nucleotides 2,109  –  2,117) of hu-
man   cyclin D1   is well conserved between species (  Fig. 4 C  ). 
To determine whether miR-17/20 directly regulates   cyclin D1 , 
  cyclin D1   mRNA  3    UTR was linked to the fi  refl  y luciferase as 
a reporter gene (  Fig. 4 D  ). Full-length and   cyclin D1   3    UTR 
fragments containing a wild-type or mutant miR-17/20  –  binding 
site were inserted into the luciferase reporter vector (  Fig. 4 D  ). 
A construct without the miRNA binding sites was used as a neg-
ative control. When introduced into MCF-7 cells, the full-length 
cyclin D1 3     UTR reporter showed a 90% reduction in lucifer-
ase activity in the miR-17/20  –  transduced cells compared with 
empty luciferase vector and negative control vector (  Fig. 4 E  ). 
The reporter vector carrying the   cyclin D1   3    UTR fragment 
  Cyclin D1   is rate-limiting in tumorigenesis induced by 
several breast oncogenes (Ras, Src, and ErbB2;   Fu et al., 2004  ). 
In view of the finding that   cyclin D1   level was reduced by 
miR-17/20 expression, we examined the relative abundance of 
  cyclin D1   and miR-17/20 in 11 different human cell lines and 16 
matched normal and tumorous human breast samples. The abun-
dance of   cyclin D1   and expression of miR-17/20 were inversely 
correlated (  Fig. 3, C and D  ). Statistical analysis showed signifi  cant 
down-regulation of miR-17/20 expression in breast tumors over 
matching normal tissue (  Fig. 3 E  ), and signifi  cant up-regulation 
of   cyclin D1   expression in breast tumors over matching normal 
tissue (  Fig. 3 F  ). There is a signifi  cant association between the 
up-regulation of expression in cyclin D1 and the down-regulation 
of miR-17/20 expression (  Fig. 3 G  ) 
  miR-17/20 represses cyclin D1 through 
a conserved 3     UTR binding site 
  To determine the mechanism by which miR-17/20 inhibited 
  cyclin D1   abundance, quantitative real-time PCR analysis was 
  Figure 3.       The inverse correlation between   cyclin D1   
abundance and miR-17/20 expression in human breast 
cancer tissues and cell lines.   (A) Western blots showed 
the repression of   cyclin D1   and AIB1 abundance by 
miR-17/20. Both anti  –  miR-17-5p and anti  –  miR-20a 
increased the expression of   cyclin D1   and AIB1 in cells. 
AIB1 is a positive control.    -tubulin was a loading control. 
(B) Cotransfection of anti  –  miR-17-5p or anti  –  miR-20a 
reversed the antiproliferative function of miR-17/20 in 
MCF-7 cells. (C) Western blots showed the high   cyclin 
D1   level in low miR-17/20  –  expressing breast cancer 
cell lines, and low   cyclin D1   in high miR-17/20 cell 
lines. A Northern blot of miRNA17/20 is shown in 
Fig. S1 (available at http://www.jcb.org/cgi/content/
full/jcb.200801079/DC1). (D) The abundances 
of   cyclin D1   and miR-17-5p/miR-20a in 16 human 
breast tumor tissues and 16 matching normal breast 
tissues were determined by Western and Northern 
blots. Tissue sample IDs were provided by the sample 
provider. Black lines indicate that intervening lanes 
have been spliced out. N, normal tissue; T, tumor tissue. 
(E) Statistically signiﬁ  cant down-regulation of miR-17/20 
expression in breast tumors over matching normal tissue. 
P = 0.004 by Wilcoxon signed rank test. The gray-
scale intensity of each band in D was obtained by 
AlphaImager software. The y axis value stands for the 
addition of miR-17-5p and miR-20a expression in each 
sample. (F) Signiﬁ  cant up-regulation of cyclin D1 ex-
pression in breast tumors over matching normal tissue. 
P = 0.001. (G) Plotting the paired difference of tumor 
and normal samples expression for each marker 
(miR-17/20 vs. cyclin D1). The exact McNemar  ’  s test 
indicates a signiﬁ   cant association between the up-
regulation of expression in cyclin D1 and the down-
regulation of miR-17/20 expression. P = 0.002.     513 CYCLIN     D1/  MICRO  RNA 17/20 REGULATORY LOOP   • Yu et al. 
course of   cyclin D1   expression and miR-17-5p induction were 
detected by Western and Northern blots, respectively (  Fig. 5 B  ). 
  Cyclin D1   protein abundance was increased at 6 h, with maxi-
mal abundance at 12 h. miR-17-5p expression increased at 6 h 
(  Fig. 5 B  ). To determine whether   cyclin D1   was required for serum-
mediated induction of miR-17-5p, a comparison was made be-
tween   cyclin D1 
   /       and   cyclin D1 
+/+     MEFs.  The  induction  of 
miR-17-5p by serum was identifi  ed in   cyclin D1 
+/+     but not 
  cyclin D1 
   /       MEFs (  Fig. 5 C  ). To determine if   cyclin D1   induced 
miR-17/20 in vivo, MMTV-  cyclin D1   transgenic mice were as-
sessed. RNAs from MMTV –  cyclin D1  – induced mammary tumors, 
and normal mouse mammary gland were compared and ana-
lyzed for miRNA expression using miRNA chips. Consistent 
with the in vitro data, the miR-17/20 cluster was up-regulated in 
the   cyclin D1    –  induced mammary tumors (  Fig. 5 D  ). 
    Cyclin D1   binds the promoter of the 
miR-17/20 cluster 
  Cyclin D1 induced miR-17/20 expression, and   cyclin D1   is 
known to regulate gene transcription through occupancy of 
a subset of gene promoters in the context of local chroma-
tin, thereby regulating cellular differentiation and prolifera-
tion (  Wang et al., 2003  ;   Hulit et al., 2004  ;   Fu et al., 2005  ). 
Chromatin immunoprecipitation assays were performed to de-
termine whether   cyclin D1   occupied the   miR-17/20   promoter 
in the context of local chromatin in human breast epithelial 
cells. MCF-10A cells were fi  xed, and a cell lysate was prepared. 
Using a cyclin D1 antibody to immunoprecipitate   cyclin D1  –
  binding DNAs, preimmune serum was used as negative control. 
DNA was amplifi  ed by real-time PCR. 3 kb of the miR-17/20 cluster 
upstream region was examined by 11 different pairs of primers, 
which divide the miR-17/20 promoter region into 11 fragments 
with the miR-17/20 binding site showed reduced luciferase 
activity in the transduced cells compared with control cells. 
Mutation of the miR-17/20 binding site abrogated repression of 
luciferase activity (  Fig. 4 E  ). 
    Cyclin D1   is required for induction of 
miR-17/20 expression 
  miR-17/20 can be induced by   c-myc   or   E2F1 ,  and  miR-17/20  in 
turn negatively regulates   E2F1   translation (  O  ’ Donnell  et al., 
2005  ;   Sylvestre et al., 2007  ).   c-myc ,  E2F ,  cyclin D1 ,  and   pRb  
are important regulators of G  0 /G 1    –  S transition of the cell cycle. 
The miR-17/20 cluster is activated by c-myc in early G  1  , and the 
E2F1 protein accumulates in late G  1.   Like   c-myc ,   cyclin D1   is 
activated early in the G  1   phase.  As   c-myc   is capable of inducing 
miR-17/20, we examined the possibility that   cyclin D1   may 
also induce miR-17/20 expression. A retroviral expression vector 
encoding   cyclin D1   was used to transduce wild-type and   cyclin 
D1 
   /       mouse embryonic fi   broblasts (MEFs) to determine 
whether   cyclin D1   was  suffi  cient to induce miR-17/20 expression. 
  Cyclin D1   overexpression was confi  rmed by Western blot-
ting (Fig. S4, available at http://www.jcb.org/cgi/content/full/
jcb.200801079/DC1), and miRNA expression was confi  rmed by 
Northern blotting (  Fig. 5 A  ). miR-17-5p expression was reduced 
to undetectable levels in   cyclin D1  
 /        cells (  Fig. 5 A  ). Cyclin D1 
transduction of   cyclin D1   
 /        cells resulted in physiological levels 
of cyclin D1 and induced miR-17-5p and miR-20a expression 
(  Fig. 5 A  , lanes 3 vs. 4). An unrelated miRNA, miR-100, showed 
no difference in expression in cyclin D1 
   /     cells by Northern 
blotting (  Fig. 5 A  ) and miRNA chip analysis (not depicted). 
  To determine whether miR-17-5p and   cyclin D1   are co-
ordinately regulated by physiological stimulation, MCF-7 cells 
were serum-starved and then stimulated by 10% FBS. The time 
  Figure 4.       miR-17/20 represses   cyclin D1   
expression through a conserved 3     UTR site.   
(A) Quantitative real-time RT-PCR assay did 
not show signiﬁ  cant difference in mRNA level 
of   cyclin D1   between miR-17/20  –  transduced 
cells and control cells. ABI1 was a positive 
control. 18S served as an internal control for 
normalization. This experiment was repeated 
three times in triplicate. Data are mean   ±   SEM. 
(B) BLASTN analysis of human and mouse 
  cyclin D1   mRNAs identiﬁ  ed a miR-17-5p  –   and 
miR-20a  –  binding site at the conserved 3     UTR 
region. (C) Sequence alignment of the miR-17-5p 
and miR-20a base-paring site in the 3     UTR of 
  cyclin D1   mRNAs. The region complementary 
to the 2  –  10 nt of miR-17/20 is highly con-
served among human, mouse, rat, and dog. 
The   “  seed  ”   sequence of miR-17/20 that is 
complementary to cyclin D1 is shown in italics 
and boxed. The mutant sequence is identical 
to the wild-type sequence except the mutated 
nucleotides are shown in red. (D) Luciferase re-
porter assay constructs. 3     UTR FL, the full-length 
3     UTR of   cyclin D1   inserted to the downstream 
of the luciferase coding region in the pGL3 
vector; 3     UTR-1, a fragment of   cyclin D1   3     
UTR containing the miR-17/20  –  binding sequence; 3     UTR-1-mu, the mutated construct identical to 3    UTR-1 but point mutated in the miR-17/20 binding site; 
3     UTR-2, another fragment of   cyclin D1   3     UTR without the miR-17/20  –  binding sequence. (E) Luciferase reporter assay showed the decreased luciferase 
activity in miR-17/20 overexpressed cells for both 3     UTR FL and 3     UTR-1 constructs, but not for the PGL-3 empty vector, 3    UTR-1-mu and 3    UTR-2 
constructs. The luciferase activity was normalized to     -galactosidase. Data are derived from three independent experiments. Values are presented as the 
mean   ±   SEM (  n   = 3). *, P   <   0.01     JCB • VOLUME 182 • NUMBER 3 • 2008  514 
cooperate with oncogenes in tumorigenesis in animal models 
(  Croce and Calin, 2005  ). Importantly, the function of individual 
miRNAs may be cell-type specifi  c. The miR-17/20 cluster has 
been found to function either as onco-miRNA or as a tumor-
suppressor depending on the cell type ( He et al., 2005 ;  O ’ Donnell 
et al., 2005  ;   Hossain et al., 2006  ). Expression of the miR-17/20 
cluster was increased by 65% in B cell lymphomas, and miR-
17/20 cooperates with c-  Myc   in lymphomagenesis (  He et al., 
2005  ). In contrast, the miR-17/20 cluster inhibited proliferation 
of the P493-6 cell line (  O  ’  Donnell et al., 2005  ). Herein, miR-
17/20 inhibited breast cancer cellular proliferation by repression 
of   cyclin D1   translation. 
 Our  fi  ndings are of importance to the understanding of 
breast tumorigenesis, as they directly link the miR-17/20 cluster 
to the regulation of the   cyclin D1   gene. Cyclin D1 plays a key 
role in regulation of the G  1    –  S phase transition and in tumorigen-
esis (  Fu et al., 2004  ). The abundance of cyclin D1 is induced by 
a broad array of oncogenic stimuli and is required for contact-
independent growth (  Albanese et al., 1995  ;   Fu et al., 2004  ). 
Cyclin D1 is required for ErbB2-induced mammary tumorigen-
esis in vivo (  Lee et al., 2000  ;   Yu et al., 2001  ). Herein, an inverse 
correlation was found between miR-17/20 and cyclin D1 in human 
breast cancer samples, in breast cancer cell lines, and in transgenic 
mice. Our fi  nding that miRNA regulate breast cancer cellular 
proliferation and contact-independent growth is consistent with 
recent fi  ndings that specifi  c miRNA can regulate breast cancer 
progression. miR-126 reduces breast tumor growth (  Tavazoie 
et al., 2008 ), miR-335 inhibits breast cancer metastasis ( Tavazoie 
et al., 2008  ), and miR-373 and miR-520c stimulate breast cancer 
cell migration and invasion by suppressing the metastasis sup-
pressor gene   CD44   (  Huang et al., 2008  ). The current studies 
provide evidence for an additional level of fi  ne control in regu-
lation of the G  1    –  S phase transition of the cell cycle. The in-
hibition of DNA synthesis by miR-17/20 was associated with a 
reduction in the proportion of cells in the S phase and an in-
creased proportion of cells in G  1   phase. Cyclin E, which, like 
 cyclin  D1 , is capable of enhancing G  1  – S  phase  transition  in 
MCF-7 cells, was not regulated by miR-17/20. As the abundance 
of   cyclin D1   is rate-limiting in MCF7 cell growth and G  1  –  S  
phase progression (  Fu et al., 2004  ), the inhibition of   cyclin D1  
expression by miR-17/20 likely contributes to the inhibition of 
DNA synthesis and cellular proliferation in breast cancer cells. 
 Both   cyclin D1   and   c-myc   are activated early in the G  1  
phase and are key regulators of the G  1  – S  phase  transition. 
  Cyclin D1   activates   E2F1   transactivation through phosphory-
lation of pRb.  E2F1  expression is induced by  c-myc  ( Matsumura 
et al., 2003  ). miR-17-5p and miR-20a limit   c-myc  – mediated  in-
duction of   E2F1   translation (  O  ’  Donnell et al., 2005  ), providing 
a mechanism to dampen reciprocal activation of   c-myc   to   E2F1.  
Our studies provide evidence for a novel level of fi  ne tuning to 
regulate the functional interactions between  cyclin D1 ,  c-myc ,  E2F , 
and miRNAs.   Cyclin D1   abundance is increased in    50%  of 
human breast cancers. The   cyclin D1   gene encodes the labile 
catalytic subunit of the holoenzyme that phosphorylates and 
inactivates the pRb protein. The pRb protein serves as a para-
digmatic tumor suppressor. The current studies are the fi  rst to 
demonstrate that   cyclin D1   abundance is controlled by miRNA. 
(  Fig. 5 E  , fragments 1  –  11). A   cyclin D1  – specifi  c binding site was 
identifi  ed at fragment 5 (  Fig. 5 E  ). Sequence analysis of this 139-
bp fragment identifi  ed multiple GC boxes upstream of fragment 
5 and two TATA boxes downstream of fragment 5. Collectively, 
these studies demonstrate that   cyclin D1   binds  to the miR-17/20 
promoter and induces miR-17/20 expression at the transcrip-
tional level. 
  Discussion 
  Several independent lines of evidence implicate miRNAs as ei-
ther tumor suppressors or collaborative oncogenes (  Calin et al., 
2004  ;   Calin and Croce, 2006  ;   Esquela-Kerscher and Slack, 2006  ; 
  Zhang et al., 2007  ). miRNAs are differentially expressed in tu-
mors, specifi  c miRNAs are located within regions of chromo-
somal deletions or rearrangements in tumors, and miRNAs can 
  Figure 5.         Cyclin D1   induces miR-17-5p and miR-20a expression.   
(A) Northern blotting showed the increased expression of miR-17-5p and 
miR-20a in the MSCV  –  cyclin D1  –  infected MEF cells. miR-100 was used as 
a negative control. tRNA served as loading control. (B) Breast cancer cell 
line MCF-7. (C)   cyclin D1 
    /       , and   cyclin D1 
+/+     MEFs were starved by 5% 
charcoal-stripped serum for 48 h, followed by 10% FBS stimulation. The 
time course examination of the cyclin D1 protein level and the miR-17-5p 
expression level were performed by Western and Northern blots, respectively. 
The results showed the induction of cyclin D1 and miR-17-5p by serum 
stimulation in the MCF-7 and   cyclin D1 
+/+     MEF cells, but not in   cyclin 
D1 
    /        MEFs. (D) miR-17-5p and miR-20a detection in the MMTV  –    cyclin D1   
transgene induced mammary tumors (  n   = 3) compared with normal mice 
mammary gland. Data from three mammary tumor samples were pre-
sented as mean   ±   SEM. (E) Real-time PCR analysis of cyclin D1 chromatin 
immunoprecipitated DNA. 11 fragments derived from chromosome 11q31 
upstream of miR-17/20 cluster were examined. For each fragment, ampli-
ﬁ  cations on chromatin before immunoprecipitation and chromatin immuno-
precipitated with preimmune serum were performed as input and negative 
control, respectively. This experiment was repeated three times; data are 
equal to mean   ±   SEM.     515 CYCLIN     D1/  MICRO  RNA 17/20 REGULATORY LOOP   • Yu et al. 
D1 in mammary gland  –  targeted cyclin D1 transgene-induced 
breast tumors. Thus, the phenotype of cellular growth may be 
determined by the ability of cyclin D1 to evade translational 
attenuation by miR-17/20. 
  Materials and methods 
  Mice and human breast samples 
  All animal experiments were done in accordance with the guidelines for 
the care and use of laboratory animals at Thomas Jefferson University. 
  Cyclin D1   
    /      mice were maintained on a mixed C57B1/6   ×   129/SvJ back-
ground as described previously (  Hulit et al., 2004  ). Genotyping was done 
on tail DNA by PCR as described previously (  Hulit et al., 2004  ).   Cyclin D1   
transgenic mice were made and maintained as described previously 
(  Wang et al., 1994  ). MMTV  –  cyclin D1 transgenic mice were obtained 
from A. Arnold (University of Connecticut, Farmington, CT). Human breast 
cancer specimens and matching normal breast tissue samples were pro-
vided by P. McCue (Thomas Jefferson Hospital, Philadelphia, PA). All the 
procedures were approved by the Institutional Review Board of Thomas 
Jefferson University. Expression for miR-17/20 and cyclin D1 in paired tumor 
and normal samples were analyzed for signiﬁ  cant up- or down-regulation 
using the Wilcoxon signed rank test. The association of down-regulation in 
miRNA expression and up-regulation in cyclin D1 expression was completed 
via the exact McNemar  ’  s test. AlphaImager (Alpha Innotech) was used for 
intensity analysis. 
  Vectors 
  miR-17/20 expression vector was provided by J. Mendell (Johns Hopkins 
University School of Medicine, Baltimore, MD) and A. Thomas-Tikhonenko 
(University of Pennsylvania, Philadelphia, PA). Human   cyclin D1   cDNAs were 
cloned into the mouse stem cell virus (MSCV)-internal ribosome entry site 
(IRES)-GFP retrovirus vector at the EcoRI site. Different lengths of wild-type and 
mutated   cyclin D1   3     UTR sequences were inserted into the XbaI  –  FseI site im-
mediately downstream of the stop codon in the pGL3 ﬁ  reﬂ  y luciferase re-
porter vector. pMSCV  puro   vector was used to express miR-17/20 cluster at the 
EcoRI site as described previously (  O  ’  Donnell et al., 2005  ). A recombinant 
plasmid that carries the bacterial     -galactosidase cDNA driven by the CMV 
promoter was used as an internal control for transfection efﬁ  ciency. 
  Oligonucleotides 
  All DNA probes were synthesized by Integrated DNA Technologies. Primer 
sequences for cyclin D1 3     UTR cloning were as follows: 3     UTR FL for-
ward, 5    -GGGCGCCAGGCAG-3    ; 3     UTR FL reverse, 5    -ACAGGA-
CAGACT-3    ; 3     UTR-1 forward, 5    -ACCATCCAGTGGAGG-3    ; 3     UTR-1 
reverse, 5    -TGGCAATGTGAGAAT-3    ; 3     UTR-2 forward, 5    -GCCGC-
AGCTCCATT-3    ; and 3     UTR-2 reverse, 5    -ATGGCTAAGAGAA-3    . The probe 
sequences for miRNA northern analysis were as follows: miR-17-5p, 5-ACTA-
CCTGCACTGTAAGCACTTTG-3    ; miR-18a, 5    -TATCTGCACTAGATGCACC-
TTA-3    ; miR-19a, 5    -TCAGTTTTGCATAGATTTGCACA-3    ; miR-19b, 5    -TCA-
GTTTTGCATGGATTTGCACA-3    ; miR-20a, 5    -CTACCTGCACTATAAAGCA-
CTTTA-3    ; miR-92, 5   -ACAGGCCGGGGACAAGTGCAATA-3    , and miR-100, 
5    - CACAAGTTCGGATCTACGGGTT-3    . siRNAs were obtained from QIA-
GEN. Target sequence for cyclin D1: 5    -AACAAGCTCA  AGTGGAACCTG-3    ; 
target sequence for negative control siRNA: 5    -AAT  TCTCCGAACGTGTC-
ACGT-3    . Anti-miR miRNA inhibitors are chemically modiﬁ  ed, single-stranded 
nucleic acids antisense to target miRNAs. Anti  –  miR-17, anti  –  miR-20, and 
negative controls were obtained from Ambion. 
  Cell culture 
    Cyclin D1   
+/+   and   cyclin D1   
    /      primary MEFs were prepared as described 
previously (  Wang et al., 2003  ). MCF-10A cells were cultured in DME/F12 
medium containing 5% horse serum, 10   μ  g/ml insulin, 20 ng/ml EGF, 100 
ng/ml choleratoxin, 0.5   μ  g/ml hydrocortisone, and 100 mg/liter of peni-
cillin and streptomycin. 293T, Hela, MCF-7, Hs578T, T47D, BT474, SKBR-3, 
MDA-MB-231, MDA-MB-361, MDA-MB-453, MDA-MB-486, and the 
NAFA cell line derived from the MMTV-NeuT mouse cells were cultured in 
DME containing penicillin and streptomycin (100 mg of each per liter) and 
supplemented with 10% FBS. 
  Retrovirus infection, siRNA/plasmid transfection, and luciferase 
reporter assay 
  Retroviral production and infection methods have been described previ-
ously in detail (  Li et al., 2006  ). The ecotropic packaging vector pSV-    –E-MLV, 
The binding site identifi  ed within the  cyclin D1  3   UTR required 
for repression by miR-17/20 is highly conserved between species. 
As the relative abundance of  cyclin D1  is tightly regulated, multiple 
distinct mechanisms are involved to control   cyclin D1   abundance, 
including transcriptional induction, posttranslational regula-
tion, and in the current studies, posttranscriptional regulation 
via miRNA. 
  The studies herein provide genetic evidence that   cyclin D1  
binds to an miRNA promoter and regulates a specifi  c miRNA 
signature. Genetic knockout of   cyclin D1   or siRNA treatment 
demonstrated that the miR-17/20 cluster is induced by cyclin D1. 
Mammary gland  –  targeted   cyclin D1   expression recapitulated this 
miRNA signature in the mammary gland tumor. In previous 
studies,   cyclin D1   was identifi  ed within chromatin of target endog-
enous gene promoters in the context of nuclear receptor binding 
sites (peroxisome proliferator  –  activated receptor    )  and  AP-1/
CRE sites (  Fu et al., 2005  ;   Wang et al., 2003  ). Herein,   cyclin D1   
was identifi  ed within the miR-17/20 promoter in the context of 
local chromatin using chromatin immunoprecipitation assays, 
extending the potential mechanisms by which cyclin D1 may 
regulate other miRNAs. 
  Previous studies have demonstrated the induction of miR-
17/20 by c-myc and E2F (  O  ’  Donnell et al., 2005  ;   Sylvestre et al., 
2007  ). The E2F family is negatively regulated by miR-17/20 
(  O  ’  Donnell et al., 2005  ;   Sylvestre et al., 2007  ). We examined 
the abundance of c-myc in miR-17/20  –  overexpressed cells and 
found the repression of c-myc by miR-17-5p (Fig. S5, available at 
http://www.jcb.org/cgi/content/full/jcb.200801079/DC1). Thus, 
four  key  regulatory  proteins — c-Myc,  E2F1, AML1  ( O ’ Donnell 
et al., 2005  ;   Fontana et al., 2007  ;   Sylvestre et al., 2007  ), and cyclin 
D1  —  converge on the miR-17/20 cluster promoter region to cre-
ate important regulatory feedback loops (  Fig. 6  ). Consistent 
with this model, translation of the cyclin D1  –  binding protein 
AIB1 is repressed by miR-17/20 (  Hossain et al., 2006  ). In turn, 
miR-17-15p/miR-20a attenuates this activity by inhibiting each 
of these upstream activators. These attenuating feedback loops 
provide mechanisms to tightly control proliferative signals. 
Herein, the expression of miR-17/20 was increased by cyclin 
  Figure 6.       miR-17/20 regulatory loops.   (A) E2F-miR-17/20 regulatory 
loop. (B) AML1-miR-17/20 regulatory loop. (C) c-Myc  –  miR-17/20 regulatory 
loop. (D) cyclin D1  –  miR-17/20 regulatory loop. Red arrows are supported 
by our data. Black arrows are supported by scientiﬁ  c literature.     JCB • VOLUME 182 • NUMBER 3 • 2008  516 
cells per sample were analyzed by ﬂ  ow cytometry with a FACScan ﬂ  ow 
cytometer (BD Biosciences). Histograms were analyzed for cell cycle com-
partments using ModFit version 2.0 (Verity Software House). 
  Chromatin immunoprecipitation 
  MCF-10A cells were cross-linked with formaldehyde (ﬁ  nal concentration of 
1%), and chromatin immunoprecipitation was performed as described pre-
viously (  Weinmann et al., 2001  ) using anti  –  cyclin D1 antibody (SC-450; 
Santa Cruz Biotechnology, Inc.). Real-time PCR was performed using the 
SYBR green PCR Master Mix kit (Applied Biosystems) to amplify the 
immunoprecipitated DNA. Sequences of primers derived from the genomic 
region upstream of the miR-17/20 cluster are provided in Table S1 (avail-
able at http://www.jcb.org/cgi/content/full/jcb.200801079/DC1). 
  Online supplemental material 
  Fig. S1 shows the low miR-17-5p and miR-20a expression in human breast 
cancer cell lines. Fig. S2 shows the cell cycle analysis of miR-17/20  –  trans-
duced MCF-10A and BT474 cells. Fig. S3 shows that inhibition of endog-
enous miR-17/20 by anti  –  miR-17-5p and anti  –  miR-20a increased cyclin 
D1 expression in MCF-7 cells. Fig. S4 shows overexpression of cyclin D1 
in the MSCV  –  cyclin D1  –  transduced cyclin D1 
    /      MEFs. Fig. S5 shows the 
inhibition of   c-myc   expression by the miR-17/20 cluster in MCF-7 cells. 
Table S1 shows primer sequences for real-time PCR ampliﬁ  cation of cyclin 
D1 chromatin immunoprecipitation assay. Online supplemental material is 
available at http://www.jcb.org/cgi/content/full/jcb.200801079/DC1. 
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which provides ecotropic packaging helper function, was used with retro-
virus to infect cells. For cellular transfection with plasmid DNA, actively 
growing cells were seeded on 12-well plates at a density of 1   ×   10 
5   cells per 
well in an antibiotic-free medium. The next day, cells were cotransfected 
using Lipofectamine 2000 (Invitrogen) with 0.5   μ  g of pGL3 and 0.1   μ  g of 
CMV/    -galactosidase plasmid. 24 h after transfection, luciferase activities 
were measured by AutoLumat (Berthold Technologies) and normalized with 
    - galactosidase. For the reverse transfection of siRNA to MCF-7 cells, Li-
pofectamine RNAiMAX was used according to the manufacturer  ’  s instruc-
tions (Invitrogen). 
  miRNA expression proﬁ  ling and data analysis 
  miRNA expression arrays were generated at Kimmel Cancer Center at 
Thomas Jefferson University and probed essentially as described previously 
(  Liu et al., 2004  ). In brief, 5   μ  g of total RNA from each sample was biotin-
labeled during reverse transcription using random hexanes. Hybridization 
was performed on an miRNA microarray chip that contained 368 probes 
in triplicate, corresponding to 245 human and mouse miRNA genes. 
All probes on these microarrays were 40-mer oligonucleotides spotted by 
contacting technologies and covalently attached to a polymeric matrix. 
Hybridization signals were detected by biotin binding of a Streptavidin  –
  Alexa 647 conjugate using a ScanArray XL5K (PerkinElmer). Scanner im-
ages were quantiﬁ   ed by the Quantarray software (PerkinElmer). Signal 
intensities were normalized and analyzed using GeneSpring software 
(Agilent Technologies). 
  miRNA Northern blot analysis 
  Northern blot analysis of miRNAs was performed as described previously 
(  Yu et al., 2005  ). In brief, total RNA (10  –  20   μ  g per lane) was loaded on 
a 15% denaturing polyacrylamide gel and electophoresed at 200 V until 
the bromophenol blue approached the bottom. The RNA was transferred 
from the gel to Hybond-N+ membrane using a semidry transfer apparatus 
(Bio-Rad Laboratories). DNA oligonucleotide probes (20  –  23 nt) were 
5    -end labeled with [    - 
32  P]ATP, and hybridization was performed using Rapid-
Hyb buffer according to the manufacturer  ’  s instructions (GE Healthcare). 
  Real time RT-PCR analysis 
  Total RNA was extracted with Trizol reagent (Invitrogen). The 7900 HT Se-
quence Detection System (Applied Biosystems) was used for quantitative RT-
PCR assay. Primers were designed using primer Express 1.5/Taqman Primer 
Design software (Applied Biosystems). The primer sequences were as fol-
lows: cyclin D1 forward, 5    -AAGCTGTGCATCTACACCGA-3    ; cyclin D1 
reverse, 5    -CTTGAGCTTGTTCACCAGGA-3    ; AIB-1 forward, 5    -AAACTCC-
ATGGGAAGACCAG-3    ; AIB-1 reverse, 5    -GTCTCGCACCTGGTATGCTA-3    ; 
18S forward, 5    -CTACCACATCCAAGGAAGGCA-3    ; and 18S reverse, 
5    -TTTTTCGTCACTACCTCCCCG-3    . 
  Western blot analysis 
  Whole-cell lysates (50   μ  g) were separated by 10% SDS-PAGE, and the pro-
teins were transferred to nitrocellulose membrane. The following antibodies 
were used for Western blotting: anti  –  cyclin D1 (Thermo Fisher Scientiﬁ  c), 
anti-AIB1 (BD Biosciences), anti-GDI (RTG Solutions), and anti-Myc (sc-40) 
and anti  –      -tubulin (sc-9104; both from Santa Cruz Biotechnology, Inc.). 
  Cell proliferation assays 
  Cells were infected with pMSCV  puro  -miR-17/20 cluster or pMSCV  puro   empty 
vector. After puromycin selection, 4   ×   10 
4   cells per milliliter were seeded into 
6-well plate in triplicate, and the cell number was counted every day for 3  –  4 d 
under microscope using a hemocytometer. For the 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium (MTT) assay, 4   ×   10 
3   cells per well were seeded 
into a 96-well plate in triplicate, and after a 24-h culture, the cell growth 
was measured by MTT bromide assay. 
  Colony formation assay 
  The same amount of miR-17/20 overexpression MCF-7 cells and control cells 
were plated in triplicate in a 6-well plate in puromycin-containing medium. 
After incubation at 37  °  C for 7  –  10 d, the colonies were stained with Crystal 
Violet solution (Allied Chemical Corporation) in methanol for 15  –  30 min. 
Colonies   >  50   μ  m in diameter were counted. 
  Cell cycle analysis 
  Cells were starved in DME supplemented with 5% charcoal-stripped serum. 
After 48 h, medium was changed with DME with 10% normal FBS. Cells 
were harvested at different time points, and cell cycle parameters were 
determined using laser scanning cytometry. Cells were processed by 
standard methods by using propidium iodide staining of cell DNA. 10,000 517 CYCLIN     D1/  MICRO  RNA 17/20 REGULATORY LOOP   • Yu et al. 
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